Osmotic Minipump

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 1503 Experts worldwide ranked by ideXlab platform

Stanley Hoffman - One of the best experts on this subject based on the ideXlab platform.

Thierry D Charlier - One of the best experts on this subject based on the ideXlab platform.

  • Research Article Fluoxetine Dose and Administration Method Differentially Affect Hippocampal Plasticity in Adult Female Rats
    2016
    Co-Authors: Jodi L Pawluski, Eva Van Donkelaar, Virginie Houbart, Marianne Fillet, Harry W M Steinbusch, Thierry D Charlier
    Abstract:

    Copyright © 2014 Jodi L. Pawluski et al.This is an open access article distributed under theCreative CommonsAttribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Selective serotonin reuptake inhibitor medications are one of the most common treatments for mood disorders. In humans, these medications are taken orally, usually once per day. Unfortunately, administration of antidepressant medications in rodent models is often through injection, oral gavage, or Minipump implant, all relatively stressful procedures. The aim of the present study was to investigate how administration of the commonly used SSRI, fluoxetine, via a wafer cookie, compares to fluoxetine administration using an Osmotic Minipump, with regards to serum drug levels and hippocampal plasticity. For this experiment, adult female Sprague-Dawley rats were divided over the two administration methods: (1) cookie and (2) Osmotic Minipump and three fluoxetine treatment doses: 0, 5, or 10mg/kg/day. Results show that a fluoxetine dose of 5mg/kg/day, but not 10mg/kg/day, results in comparable serum levels of fluoxetine and its active metabolite norfluoxetine between the two administration methods. Furthermore, Minipump administration of fluoxetine resulted in higher levels of cell proliferation in the granule cell layer (GCL) a

  • Fluoxetine dose and administration method differentially affect hippocampal plasticity in adult female rats.
    Neural plasticity, 2013
    Co-Authors: Jodi L Pawluski, Eva Van Donkelaar, Zipporah Abrams, Virginie Houbart, Marianne Fillet, Harry W M Steinbusch, Thierry D Charlier
    Abstract:

    Selective serotonin reuptake inhibitor medications are one of the most common treatments for mood disorders. In humans, these medications are taken orally, usually once per day. Unfortunately, administration of antidepressant medications in rodent models is often through injection, oral gavage, or Minipump implant, all relatively stressful procedures. The aim of the present study was to investigate how administration of the commonly used SSRI, fluoxetine, via a wafer cookie, compares to fluoxetine administration using an Osmotic Minipump, with regards to serum drug levels and hippocampal plasticity. For this experiment, adult female Sprague-Dawley rats were divided over the two administration methods: (1) cookie and (2) Osmotic Minipump and three fluoxetine treatment doses: 0, 5, or 10 mg/kg/day. Results show that a fluoxetine dose of 5 mg/kg/day, but not 10 mg/kg/day, results in comparable serum levels of fluoxetine and its active metabolite norfluoxetine between the two administration methods. Furthermore, Minipump administration of fluoxetine resulted in higher levels of cell proliferation in the granule cell layer (GCL) at a 5 mg dose compared to a 10 mg dose. Synaptophysin expression in the GCL, but not CA3, was significantly lower after fluoxetine treatment, regardless of administration method. These data suggest that the administration method and dose of fluoxetine can differentially affect hippocampal plasticity in the adult female rat.

Richard M. Silver - One of the best experts on this subject based on the ideXlab platform.

Eva Csongradi - One of the best experts on this subject based on the ideXlab platform.

  • expression of heme oxygenase 1 in thick ascending loop of henle attenuates angiotensin ii dependent hypertension
    Journal of The American Society of Nephrology, 2012
    Co-Authors: David E Stec, Heather A Drummond, Monette U Gousette, Megan V Storm, Nader G Abraham, Eva Csongradi
    Abstract:

    Kidney-specific induction of heme oxygenase-1 (HO-1) attenuates the development of angiotensin II (Ang II) -dependent hypertension, but the relative contribution of vascular versus tubular induction of HO-1 is unknown. To determine the specific contribution of thick ascending loop of Henle (TALH) -derived HO-1, we generated a transgenic mouse in which the uromodulin promoter controlled expression of human HO-1. Quantitative RT-PCR and confocal microscopy confirmed successful localization of the HO-1 transgene to TALH tubule segments. Medullary HO activity, but not cortical HO activity, was significantly higher in transgenic mice than control mice. Enhanced TALH HO-1 attenuated the hypertension induced by Ang II delivered by an Osmotic Minipump for 10 days (13963 versus 15362 mmHg in the transgenic and control mice, respectively; P,0.05). The lower blood pressure in transgenic mice associated with a 60% decrease in medullary NKCC2 transporter expression determined by Western blot. Transgenic mice also exhibited a 36% decrease in ouabain-sensitive sodium reabsorption and a significantly attenuated response to furosemide in isolated TALH segments,. In summary, these results show that increased levels of HO-1 in the TALH can lower blood pressure by a mechanism that may include alterations in NKCC2-dependent sodium reabsorption.

  • Renal Inhibition of Heme Oxygenase-1 Increases Blood Pressure in Angiotensin II-Dependent Hypertension
    Hindawi Limited, 2012
    Co-Authors: Eva Csongradi, Megan V Storm, David E Stec
    Abstract:

    The goal of this study was to test the hypothesis that renal medullary heme oxygenase (HO) acts as a buffer against Ang-II dependent hypertension. To test this hypothesis, renal medullary HO activity was blocked using QC-13, an imidazole-dioxolane HO-1 inhibitor, or SnMP, a classical porphyrin based HO inhibitor. HO inhibitors were infused via IRMI catheters throughout the study starting 3 days prior to implantation of an Osmotic Minipump which delivered Ang II or saline vehicle. MAP was increased by Ang II infusion and further increased by IRMI infusion of QC-13 or SnMP. MAP averaged 113±3, 120±7, 141±2, 153±2, and 154±3 mmHg in vehicle, vehicle + IRMI QC-13, Ang II, Ang II + IRMI QC-13, and Ang II + IRMI SnMP treated mice, respectively (n=6). Inhibition of renal medullary HO activity with QC-13 in Ang II infused mice was also associated with a significant increase in superoxide production as well as significant decreases in antioxidant enzymes catalase and MnSOD. These results demonstrate that renal inhibition of HO exacerbates Ang II dependent hypertension through a mechanism which is associated with increases in superoxide production and decreases in antioxidant enzymes

Richard P. Visconti - One of the best experts on this subject based on the ideXlab platform.

Related terms

Osmotic Minipump - 15 days free trial to Access Experts & Abstracts